Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Hear AtLast Holdings, Inc. (OTC: HRAL).

Full DD Report for HRAL

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-180.050.100.100.05500
2018-12-170.070.070.070.0710,409
2018-12-14N/A0.10N/AN/A15
2018-12-13N/A0.10N/AN/A0
2018-12-12N/A0.10N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-134,99010,00649.8701Short
2018-11-0125051248.8281Short
2018-10-291,0001,02098.0392Short
2018-10-1610010694.3396Short
2018-10-0110019750.7614Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HRAL.


About Hear AtLast Holdings, Inc. (OTC: HRAL)

Logo for Hear AtLast Holdings, Inc. (OTC: HRAL)

Hearing aid instrument reseller to hearing impaired individuals. HearAtLast also licenses to other Hearing Aid instrument sellers.

 

 

 

Current Management

  • Aldo Rotondi / President
  • Peter Wanner / Treasurer
  • Matteo Sacco /

Current Share Structure

  • Market Cap: $80,005 - 03/16/2018
  • Authorized: 500,000,000 - 11/01/2017
  • Issue and Outstanding: 1,000,066 - 11/01/2017

 


Recent Filings from (OTC: HRAL)

Supplemental Information - HRAL March 31, 2016 Annual OTC Guideline Report
Filing Type: Supplemental Information - HRAL March 31, 2016 Annual OTC Guideline ReportFiling Source: OTC Markets
Filing Date: March, 08 2018
Supplemental Information - HRAL Dec 31 2017 Q3 OTC Guideline Report
Filing Type: Supplemental Information - HRAL Dec 31 2017 Q3 OTC Guideline ReportFiling Source: OTC Markets
Filing Date: March, 04 2018
Quarterly Report - HRAL Q3 Financial Report Dec 31 2017
Filing Type: Quarterly Report - HRAL Q3 Financial Report Dec 31 2017Filing Source: OTC Markets
Filing Date: March, 04 2018
Supplemental Information - HRAL September 30 2017 Q2 OTC Guideline Report
Filing Type: Supplemental Information - HRAL September 30 2017 Q2 OTC Guideline ReportFiling Source: OTC Markets
Filing Date: March, 04 2018
Quarterly Report - HRAL Q2 Financial Report Sept 30 2017
Filing Type: Quarterly Report - HRAL Q2 Financial Report Sept 30 2017Filing Source: OTC Markets
Filing Date: March, 04 2018
Supplemental Information - HRAL June 30 2017 Q1 OTC Guideline Report
Filing Type: Supplemental Information - HRAL June 30 2017 Q1 OTC Guideline ReportFiling Source: OTC Markets
Filing Date: March, 04 2018
Quarterly Report - HRAL June 30 2017 Q1 Financial Statements
Filing Type: Quarterly Report - HRAL June 30 2017 Q1 Financial StatementsFiling Source: OTC Markets
Filing Date: March, 04 2018
Supplemental Information - HRAL OTC Guidelines Report March 31 2017
Filing Type: Supplemental Information - HRAL OTC Guidelines Report March 31 2017Filing Source: OTC Markets
Filing Date: March, 04 2018
Annual Report - HRAL Annual Mar 31 2016 financial report
Filing Type: Annual Report - HRAL Annual Mar 31 2016 financial reportFiling Source: OTC Markets
Filing Date: March, 04 2018
Annual Report - HRAL Annual Report for March 31 2016
Filing Type: Annual Report - HRAL Annual Report for March 31 2016Filing Source: OTC Markets
Filing Date: March, 04 2018

 

 


Daily Technical Chart for (OTC: HRAL)

Daily Technical Chart for (OTC: HRAL)


Stay tuned for daily updates and more on (OTC: HRAL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: HRAL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HRAL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HRAL and does not buy, sell, or trade any shares of HRAL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/